Full-Time

Senior Machine Learning Engineer

Posted on 10/18/2023

Absci

Absci

51-200 employees

Biotech company specializing in protein production

No salary listed

Senior

Remote in USA + 1 more

More locations: Vancouver, WA, USA

The position is remote within the United States, Canada, Serbia, or Switzerland, with hybrid work available in Vancouver, WA;, New York City; or Belgrade Serbia. Absci is a global company with headquarters in the Pacific Northwest US and an AI Research Lab in New York City.

Category
Applied Machine Learning
Deep Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
Python
Requirements
  • 4-8+ years of experience designing and building production grade software solutions
  • 4+ years of experience working on ML/AI Systems
  • Proven Track record of creating an engineering project roadmaps and executing on it by delivering high impact work
  • Proven track record of fostering high performing teams and upleveling those around you by coaching and mentoring less experienced engineers on the team
  • Experience building ML/AI systems within the Python ecosystem in the cloud, on-premises, or hybrid
  • Excellent written and oral communication skills
  • Comfortable working in a fast-paced work environment with high autonomy and matching accountability
Responsibilities
  • Act as the technical lead and owner for specific problem spaces in AI workflows
  • Building ML/AI software systems using various tools
  • Work with interdisciplinary teams to build consensus and define achievable product roadmaps
  • Set and implement strategy to deliver on team's objectives and manage technical debt
  • Mentor and coach less experienced engineers on the team

AbSci improves protein expression and biomanufacturing in the biotech industry with its advanced platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system for precise control over protein production. Its standout product, SoluPure, is a chromatography-free purification method that streamlines the protein purification process, making it faster and more cost-effective. AbSci differentiates itself by aiming to replace traditional mammalian expression systems with more efficient solutions, providing significant cost savings to clients. The company's goal is to challenge established practices in biotech and create better tools for drug discovery and manufacturing.

Company Size

51-200

Company Stage

IPO

Headquarters

Vancouver, Washington

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Absci's partnerships with AMD and Owkin enhance AI-driven drug discovery capabilities.
  • Generative AI collaborations with MSK and Twist Bioscience accelerate novel therapeutic development.
  • Increased adoption of AI and synthetic biology boosts Absci's innovative drug designs.

What critics are saying

  • Growing competition in AI-driven drug discovery may impact Absci's market share.
  • Dependence on partnerships could pose risks if collaborations don't yield results.
  • Rapid tech advancements could render Absci's current technologies obsolete.

What makes Absci unique

  • Absci uses AI and synthetic biology for novel protein-based drug discovery.
  • Their SoluPure method simplifies protein purification, reducing production time and costs.
  • Absci's high-throughput workflow generates active protein products in just three months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
GlobeNewswire
Jan 10th, 2025
Absci And Owkin Synergize Leading Techbio Platforms To Advance Generative Ai Drug Discovery

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids

Aitech365
Jan 9th, 2025
Absci & AMD Announce Collaboration to Boost AI Drug Discovery

Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.

SiliconANGLE
Jan 8th, 2025
AMD invests $20M in Absci's AI drug discovery

AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.

GlobeNewswire
Jan 8th, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.

247 Market News
Jan 8th, 2025
"Top Stocks Traders Are Buying Today: SANA, SYTA, CURR, EONR, and ABSI - Hot Picks Driving the Market"

Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).

INACTIVE